Oncimmune makes EarlyCDT-Liver Test commercially available in the U.S.
Category: #health  By Shikha Sinha  Date: 2018-05-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oncimmune makes EarlyCDT-Liver Test commercially available in the U.S.

Leading early cancer diagnostics company, Oncimmune Holdings PLC, has recently announced that it has launched a liver cancer biopsy platform which is based on its exclusive EarlyCDT liquid biopsy platform technology. Reportedly, the company has completed the development of its EarlyCDT®-Liver test for HCC (hepatocellular carcinoma), which will now be commercially available in the U.S. market.

Sources reveal that EarlyCDT®-Liver is Oncimmune’s second test, after EarlyCDT®-Lung which has shown proven results and has detected cancer up to four years earlier than other methods. The test has high specificity at ninety seven percent which can result into positive test with high degree of certainty.

The high specificity significantly complements the current imaging detection methods as the AFP (alpha fetoprotein) diagnostic test used in Asia.

According to the reliable reports, EarlyCDT®-Liver test is blood test which is complementary to cancer diagnosis via imaging. The test is also expected to aid in the risk assessment & early detection of hepatocellular carcinoma in patients with hepatic lesions not more than 1cm.

EarlyCDT®-Liver will be available through Oncimmune’s current distribution network in the U.S. at the initial stages. The company will further expand its distribution network in the U.S. and other international markets.

Geoffrey Hamilton-Fairley, CEO, Oncimmune, revealed in a company statement that the firm is pleased to announce the commercial availability of EarlyCDT-Liver test. He further exclaimed that a majority of HCC cases are detected in the later stages of the disease or once symptoms appear.

According to Hamilton-Fairley, the test can detect liver cancer in its early stages of development, in turn providing patients with greater chance of more treatment methods and better prognosis.

For the record, liver cancer is 2nd most common cause of cancer deaths across the world. It is particularly more prevalent in Eastern & South-Eastern Asia and is highly associated with smoking, consumption of alcohol, and hepatitis B and C infections.



About Author

Shikha Sinha

Email: [email protected]   

Shikha Sinha

Shikha currently manages content operations for a series of news and business portals including MSF, Algosonline, and the like. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market resea...

Read More

More News By Shikha Sinha

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Shikha Sinha

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Shikha Sinha

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Shikha Sinha

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...